Stress-eating (eating more or more unhealthily in order to accommodate to stress), contributes to the development and maintenance of obesity. The effect of comprehensive weight loss interventions on changes in stress-eating as well as the contributing role of stress-eating on weight reduction has not been examined. The impact of the 8-week intensive phase of the Healthy Lifestyle Community Programme (HLCP, cohort 1) on emotional, external and restrained eating, as expressions of stress-eating was evaluated in a non-randomized controlled trial. Intervention: 14 seminars (twice per week, including practical units), complemented by stress-regulation and cooking workshops and coaching sessions empowering participants to change their behaviour towards a healthy plant-based diet (ad libitum), stress regulation, regular exercise and to focus on social support. Participants were recruited from the general population. In the intervention group, 91 participants (IG; age: 56 ± 10, 77% female) and in the control group, 52 (CG; age: 62 ± 14, 57% female) were enrolled. At baseline, participants of the IG reported higher levels of stress (9.7 ± 5.4 points [P] vs. 7.6 ± 6.2; p < 0.011), and of emotional eating (27.9 ± 9.4 vs. 20.0 ± 7.1; p < 0.001) and external eating (29.1 ± 4.9 vs. 25.5 ± 5.6; p < 0.001) than participants of the CG. Within 8 weeks, in the IG, scores of emotional eating (− 3.5 ± 5.4 P) and external eating significantly decreased (= − 2.0 ± 3.8 P), while restrained eating increased (2.7 ± 5.0 P; p for all < 0.001). Weight change was negatively correlated with change of external eating (R2 = 0.045; CC = − 0.285; p = 0.014), indicating that a greater weight change was associated with a smaller change of external eating. This is the first study to prospectively investigate the role of stress-eating on the weight reduction effect of comprehensive lifestyle interventions. Our data confirm that overweight is associated with EE and external eating and suggest that the HLCP is capable to reduce both, weight and stress-eating.
Zusammenfassung
Hintergrund. Zur qualitätsbasierten
Weiterentwicklungeffizienter und bedarfs
orientierter Maßnahmen der betrieblichen
Gesundheitsförderung (BGF) ist es von
Interesse, einen Einblick in Ihren Aufbau,
die Ausgestaltung und den Ablauf der
Maßnahmender letztenzwei Jahrzehntezu
erlangen.
Zielsetzung. Auf Basis der arbeitsschutzori
entierten Leitliniendes GKV-Spitzenverbands
wird untersucht, ob vor der Umsetzung
von BGF-Maßnahmen Bedarfserhebungen
mittels Ist-Analysen durchgeführt wurden.
Zusätzlich wird betrachtet,ob die Analysen
„weiche“ Faktoren wie Kultur, Führung und
Beziehungsklima beinhalten. Weiter wird
analysiert, welche wissenschaftlichenTheori
en undModelle denMaßnahmenzugrunde
liegen. Zudem führt die Untersuchungeine
Wirksamkeitsbetrachtungdurch, um zu
ermitteln, welche Effekte die Maßnahmen
erzielten.
Methode. Das vorliegende Literatur-Review
untersucht wissenschaftlichevaluierte BGF
Maßnahmenaus den Jahren 2000–2020.
Hierzu wurde eine systematischeLitera
turrecherche in den zwei elektronischen
DatenbankenScopus und Web of Science
für den benannten Publikationszeitraum
durchgeführt.
Ergebnisse. Die Einschlusskriterienerfüllten
41Artikel.Nur4derStudienführteneine
Ist-Analyse zur Bedarfsbestimmung von
BGF-Maßnahmendurch. 25 Studien führten
Ist-Analysen im Rahmen der Maßnahmen
durch, alle waren arbeitsschutzorientiert.Vier
Studien inkludierten in ihrer Erhebung zu
Beginn Teilaspektevon weichen Faktoren. In
12 Studienwurdenden evaluiertenInterven
tionen unterschiedliche wissenschaftliche
Theorien und Modelle zugrunde gelegt. Alle
Studien berichtetenmindestensfür einzelne
Untersuchungsparametervon positiven
Effekten.
Schlussfolgerung. Vor dem Hintergrund
des Strukturwandels der Wirtschaft und der
beständig zunehmenden Humanisierung
der Arbeit spielen wissenschaftsbasierte
Analyseinstrumentezur Bedarfsbestimmung
eine große Rolle. Zukünftige Analyseinstru
mentesolltenvon derWissenschaftkonzipiert
und erprobt werden und zusätzlich zur
Arbeitsschutzorientierung die immateriellen,
weichen Faktoren Kultur, Führung und
Beziehungsklima beinhalten. Trotz der
Empfehlungen, Maßnahmenauf Grundlage
von Theorien und Modellen zu konzipieren,
wurde dieses Potenzial von nur wenigen
wissenschaftlichevaluiertenStudien genutzt.
Die Wirksamkeitsbetrachtungzeigt, dass alle
Studien mindestensfür Teile Ihrer Evaluation
von positiven Effekten berichten. Dieses
Untersuchungsergebnisdes Reviewsweist auf
ein Publikationsbiashin
Hintergrund.ZurQualitätssicherungund
WeiterentwicklungvonBGF-Maßnahmen
(betrieblicheGesundheitsförderung) istes
vonInteresse,einenÜberblicküberwissen
schaftlichuntersuchteBGF-Maßnahmenin
denletztenzweiJahrzehntenzuerlangen.
Zielsetzung.WissenschaftlichevaluierteBGF
MaßnahmenausdenJahren2000–2020wer
denmithilfederinderPraxisdurchdenGKV
SpitzenverbandeingesetztenThemenfelder
aufdiethematischenEntwicklungen,den
Nutzen,aberauchdieSchwächenfürdie
ÜbertragbarkeitindiePraxishinanalysiert.
Methode.EinesystematischeLiteraturrecher
chefürdenPublikationszeitraumzwischen
2000und2020wurdeinzweielektronischen
Datenbankendurchgeführt.
Ergebnisse.DieEinschlusskriterienerfüllten
41Artikel.DiemeistenderindenStudien
durchgeführtenundevaluiertenBGF
MaßnahmenwarenkeineEinzelmaßnahmen,
sondernstelltenProgrammedar. Inihnen
wurdenmehrereThemenfeldergleichzeitig
adressiert.Insgesamtzeigtensichdieinden
StudienuntersuchtenBGF-Maßnahmensehr
heterogen.ZumEndedesUntersuchungszeit
raumesnahmdieAnzahlanPublikationen
zu.
Schlussfolgerung.DieimLeitfadenPräventi
onvorgegebenenBGF-Themenfeldersindbis
aufeinThemenfeldausgewogenvertreten.
DieStudienzudenBGF-Maßnahmen
sindbezogenaufdieVerständlichkeitder
angewendetenDidaktikundMethodikoft
nureingeschränktnachvollziehbarund
somitschwerindieorganisationalePraxis
übertragbar.
Background
Chronic low-grade inflammation is associated with an increased risk of chronic disease and mortality. The objective of the study was to test the effect of a healthy lifestyle intervention on biomarkers of inflammation (among other risk markers).
Methods
We conducted a non-randomized controlled trial with mostly middle-aged and elderly participants from the general population in rural northwest Germany (intervention: n = 114; control: n = 87). The intervention consisted of a 1-year lifestyle programme focusing on diet (largely plant-based; strongest emphasis), physical activity, stress management, and social support. High-sensitivity C-reactive protein (hs-CRP) was assessed at baseline, 10 weeks, 6 months, and 1 year. Homocysteine (Hcy) was assessed at baseline, 10 weeks, and 1 year. Adiponectin (Apn) was assessed at baseline and 10 weeks. An exploratory analysis of these inflammatory markers assessing the between-group differences with ANCOVA was conducted.
Results
The 1-year trajectory of hs-CRP was significantly lower in the intervention group compared to control (between-group difference: -0.8 (95% CI -1.2, -0.3) mg/l; p = 0.001; adjusted for baseline). The 1-year trajectory of Hcy was non-significantly higher in the intervention compared to control (between-group difference: 0.2 (95% CI -0.3, 0.7) µmol/l; p = 0.439; adjusted for baseline). From baseline to 10 weeks, Apn decreased significantly more in the intervention group compared to control (between-group difference: -1.6 (95% CI -2.7, -0.5) µg/ml; p = 0.004; adjusted for baseline).
Conclusions
Our study shows that healthy lifestyle changes can lower hs-CRP and Apn levels and are unlikely to significantly affect Hcy levels within 1 year.
Trial registration
German Clinical Trials Register (DRKS; reference: DRKS00018775, registered 12 Sept 2019; retrospectively registered; www.drks.de).
Background: Establishing a healthy lifestyle has a great potential to reduce the prevalence of non-communicable diseases (NCDs) and their risk factors. NCDs contribute immensely to the economic costs of the health care system arising from therapy, medication use, and productivity loss.
Aim: The aim of this study was to evaluate the effect of the Healthy Lifestyle Community Program (cohort 2; HLCP-2) on medication use and consequently on medication costs for selected NCDs (diabetes, hypertension, and dyslipidemia).
Methods: Data stem from a 24-month non-randomised, controlled intervention trial aiming to improve risk factors for NCDs. Participants completed questionnaires at six measurement time points assessing medication use, from which costs were calculated. The following medication groups were included in the analysis as NCD medication: glucose-lowering medications (GLM), antihypertensive drugs (AHD) and lipid-lowering drugs (LLD). Statistical tests for inter- and intra-group comparison and multiple regression analysis were performed.
Results: In total, 118 participants (intervention group [IG]: n = 79; control group [CG]: n = 39) were considered. Compared to baseline medication use decreased slightly in the IG and increased in the CG. Costs for NCD medication were significantly lower in the IG than in the CG after 6 (p = 0.004), 12 (p = 0.040), 18 (p = 0.003) and 24 months (p = 0.008). After multiple regression analysis and adjusting for confounders, change of costs differed significantly between the groups in all final models.
Conclusion: The HLCP-2 was able to moderately prevent an increase of medication use and thus reduce costs for medication to treat NCDs with the greatest impact on AHD.
Non-communicable diseases (NCD) are associated with high costs for healthcare systems. We evaluated changes in total costs, comprising direct and indirect costs, due to a 24-month non-randomized, controlled lifestyle intervention trial with six measurement time points aiming to improve the risk profile for NCDs. Overall, 187 individuals from the general population aged ≥18 years were assigned to either the intervention group (IG; n = 112), receiving a 10-week intensive lifestyle intervention focusing on a healthy, plant-based diet; physical activity; stress management; and community support, followed by a 22-month follow-up phase including monthly seminars, or a control group (CG; n = 75) without intervention. The complete data sets of 118 participants (IG: n = 79; CG: n = 39) were analyzed. At baseline, total costs per person amounted to 67.80 ± 69.17 EUR in the IG and 48.73 ± 54.41 EUR in the CG per week. The reduction in total costs was significantly greater in the IG compared to the CG after 10 weeks (p = 0.012) and 6 months (p = 0.004), whereas direct costs differed significantly after 10 weeks (p = 0.017), 6 months (p = 0.041) and 12 months (p = 0.012) between the groups. The HLCP-2 was able to reduce health-related economic costs, primarily due to the reduction in direct costs.